Literature DB >> 18982334

Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders.

Thomas G Beach1, Charles L White, Christa L Hladik, Marwan N Sabbagh, Donald J Connor, Holly A Shill, Lucia I Sue, Jeanne Sasse, Jyothi Bachalakuri, Jonette Henry-Watson, Haru Akiyama, Charles H Adler.   

Abstract

Involvement of the olfactory bulb by Lewy-type alpha-synucleinopathy (LTS) is known to occur at an early stage of Parkinson's disease (PD) and Lewy body disorders and is therefore of potential usefulness diagnostically. An accurate estimate of the specificity and sensitivity of this change has not previously been available. We performed immunohistochemical alpha-synuclein staining of the olfactory bulb in 328 deceased individuals. All cases had received an initial neuropathological examination that included alpha-synuclein immunohistochemical staining on sections from brainstem, limbic and neocortical regions, but excluded olfactory bulb. These cases had been classified based on their clinical characteristics and brain regional distribution and density of LTS, as PD, dementia with Lewy bodies (DLB), Alzheimer's disease with LTS (ADLS), Alzheimer's disease without LTS (ADNLS), incidental Lewy body disease (ILBD) and elderly control subjects. The numbers of cases found to be positive and negative, respectively, for olfactory bulb LTS were: PD 55/3; DLB 34/1; ADLS 37/5; ADNLS 19/84; ILBD 14/7; elderly control subjects 5/64. The sensitivities and specificities were, respectively: 95 and 91% for PD versus elderly control; 97 and 91% for DLB versus elderly control; 88 and 91% for ADLS versus elderly control; 88 and 81% for ADLS versus ADNLS; 67 and 91% for ILBD versus elderly control. Olfactory bulb synucleinopathy density scores correlated significantly with synucleinopathy scores in all other brain regions (Spearman R values between 0.46 and 0.78) as well as with scores on the Mini-Mental State Examination and Part 3 of the Unified Parkinson's Disease Rating Scale (Spearman R -0.27, 0.35, respectively). It is concluded that olfactory bulb LTS accurately predicts the presence of LTS in other brain regions. It is suggested that olfactory bulb biopsy be considered to confirm the diagnosis in PD subjects being assessed for surgical therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18982334      PMCID: PMC2631085          DOI: 10.1007/s00401-008-0450-7

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  39 in total

Review 1.  Olfaction in neurodegenerative disorder.

Authors:  Christopher Hawkes
Journal:  Adv Otorhinolaryngol       Date:  2006

2.  Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects.

Authors:  A Bloch; A Probst; H Bissig; H Adams; M Tolnay
Journal:  Neuropathol Appl Neurobiol       Date:  2006-06       Impact factor: 8.090

Review 3.  Nonmotor complications in Parkinson's disease.

Authors:  Charles H Adler
Journal:  Mov Disord       Date:  2005       Impact factor: 10.338

Review 4.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

Review 5.  Surgical treatment of Parkinson's disease.

Authors:  J A Obeso; M C Rodríguez; A Gorospe; J Guridi; L Alvarez; R Macias
Journal:  Baillieres Clin Neurol       Date:  1997-04

Review 6.  The neuropathology of parkinsonism: an overview.

Authors:  M E Cornford; L Chang; B L Miller
Journal:  Brain Cogn       Date:  1995-08       Impact factor: 2.310

Review 7.  Diagnostic criteria for Parkinson disease.

Authors:  D J Gelb; E Oliver; S Gilman
Journal:  Arch Neurol       Date:  1999-01

8.  The anterior olfactory nucleus in Parkinson's disease.

Authors:  R K Pearce; C H Hawkes; S E Daniel
Journal:  Mov Disord       Date:  1995-05       Impact factor: 10.338

9.  Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study.

Authors:  I Litvan; A MacIntyre; C G Goetz; G K Wenning; K Jellinger; M Verny; J J Bartko; J Jankovic; A McKee; J P Brandel; K R Chaudhuri; E C Lai; L D'Olhaberriague; R K Pearce; Y Agid
Journal:  Arch Neurol       Date:  1998-07

Review 10.  Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Authors:  I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada
Journal:  Neurology       Date:  2005-10-19       Impact factor: 9.910

View more
  75 in total

1.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

Review 2.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

3.  Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease.

Authors:  Steven E Arnold; Edward B Lee; Paul J Moberg; Lauren Stutzbach; Hala Kazi; Li-Ying Han; Virginia M Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

Review 4.  Advances in Biomarker Research in Parkinson's Disease.

Authors:  Shyamal H Mehta; Charles H Adler
Journal:  Curr Neurol Neurosci Rep       Date:  2016-01       Impact factor: 5.081

Review 5.  Precision medicine for disease modification in Parkinson disease.

Authors:  Alberto J Espay; Patrik Brundin; Anthony E Lang
Journal:  Nat Rev Neurol       Date:  2017-01-20       Impact factor: 42.937

Review 6.  Neuropathobiology of non-motor symptoms in Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-15       Impact factor: 3.575

7.  Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies.

Authors:  Lih-Fen Lue; Douglas G Walker; Charles H Adler; Holly Shill; Hung Tran; Haruhiko Akiyama; Lucia I Sue; John Caviness; Marwan N Sabbagh; Thomas G Beach
Journal:  Brain Pathol       Date:  2012-04-12       Impact factor: 6.508

8.  Neocortical Lewy bodies are associated with impaired odor identification in community-dwelling elders without clinical PD.

Authors:  Sukriti Nag; Lei Yu; Veronique G VanderHorst; Julie A Schneider; David A Bennett; Aron S Buchman; Robert S Wilson
Journal:  J Neurol       Date:  2019-09-18       Impact factor: 4.849

9.  Late stages of hematopoiesis and B cell lymphopoiesis are regulated by α-synuclein, a key player in Parkinson's disease.

Authors:  Wenbin Xiao; Afshin Shameli; Clifford V Harding; Howard J Meyerson; Robert W Maitta
Journal:  Immunobiology       Date:  2014-07-22       Impact factor: 3.144

10.  Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms.

Authors:  Thibaud Lebouvier; Michel Neunlist; Stanislas Bruley des Varannes; Emmanuel Coron; Anne Drouard; Jean-Michel N'Guyen; Tanguy Chaumette; Maddalena Tasselli; Sébastien Paillusson; Mathurin Flamand; Jean-Paul Galmiche; Philippe Damier; Pascal Derkinderen
Journal:  PLoS One       Date:  2010-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.